Masih v. Perrigo Company PLC

CourtDistrict Court, S.D. New York
DecidedJanuary 23, 2020
Docket1:19-cv-00070
StatusUnknown

This text of Masih v. Perrigo Company PLC (Masih v. Perrigo Company PLC) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Masih v. Perrigo Company PLC, (S.D.N.Y. 2020).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -------------------------------------- X : : IN RE PERRIGO COMPANY PLC SECURITIES : LITIGATION : 19cv70 (DLC) : : OPINION AND ORDER -------------------------------------- X

APPEARANCES

For the plaintiffs: Saxena White P.A. Steven B. Singer Kyla Grant Joshua H. Saltzman 10 Bank Street, Suite 882 White Plains, NY 10606

Maya Saxena Joseph E. White, III Lester R. Hooker Dianne M. Pitre 7777 Glades Road, Suite 300 Boca Raton, FL 33434

Klausner Kaufman Jensen & Levinson Robert D. Klausner 7080 Northwest 4th Street Plantation, FL 33317

For defendant Perrigo Company PLC: Fried, Frank, Harris, Shriver & Jacobson LLP Samuel P. Groner One New York Plaza New York, NY 10004

James D. Wareham James E. Anklam 801 17th Street, NW Washington, DC 20006

For defendant Murray S. Kessler: Simpson Thacher & Bartlett LLP Joseph M. McLaughlin Shannon K. McGovern 425 Lexington Avenue New York, NY 10017

For defendant Uwe Roehrhoff: McDermott Will & Emery LLP Andrew B. Kratenstein 340 Madison Avenue New York, NY 10173

For defendant Ronald L. Winowiecki: Dechert LLP Hector Gonzalez Three Bryant Park 1095 Avenue of the Americas New York, NY 10036

Angelia Liu 35 West Wacker Drive Suite 3400 Chicago, IL 60601

DENISE COTE, District Judge:

Investors in Perrigo Company PLC (“Perrigo”) have brought a federal securities class action against the company, its CEO Murray S. Kessler, its former CEO Uwe Roehrhoff, and its former CFO Ronald L. Winowiecki. They allege that Perrigo’s March 1, 2018 Form 10-K and November 8, 2018 Form 10-Q failed adequately to disclose that Irish tax authorities had determined that Perrigo owed nearly $2 billion in back taxes. The defendants have moved to dismiss for failure to state a claim pursuant to Fed. R. Civ. P. 12(b)(6). For the reasons that follow, defendants’ motion to dismiss the claim arising from the Form 10-K filing is granted, as is the motion to dismiss all claims against defendant Roehrhoff.

Background The following facts are drawn from the Second Amended Complaint (“SAC”) and documents relied upon by the SAC. For the purposes of deciding this motion, plaintiffs’ factual allegations are accepted as true and all reasonable inferences are drawn in plaintiffs’ favor. I. Perrigo’s Treatment of $6 Billion in Tysabri Proceeds as Trading Income In December 2013, Perrigo’s predecessor entity purchased the Ireland-based Elan Corporation PLC (“Elan”), allowing Perrigo to establish its tax domicile in Ireland. Shortly before the acquisition, Elan had sold its stake in the multiple sclerosis drug Tysabri to Biogen Idec. Inc. (“Biogen”), for an up-front payment of over $3.2 billion, plus contingent royalty payments. In its tax returns, Perrigo treated over $6.0 billion

in proceeds from the Tysabri sale as “trading income,” subject to a $12.5% tax rate under Irish law. Capital gains, by contrast, are subject to a 33.0% tax rate. In November 2017, the Irish Office of the Revenue Commissioners (“Irish Revenue”) -- the Irish equivalent of the Internal Revenue Service -- commenced an audit of Perrigo’s 2012 and 2013 taxes. A November 20, 2017 notification that Irish Revenue sent to Perrigo described the scope of the audit as “Corporation Tax (Primary area of review: intellectual property;

treatment and disposal).” A November 29, 2017 message from Irish Revenue “detail[ed] the areas [the auditors] would like to review on the opening day of the audit.” The message put Perrigo on notice of Irish Revenue’s interest in the sale of Tysabri to Biogen and the treatment of the proceeds of that sale. As relevant here, the November 29 message made the following requests: [M]y colleagues . . . have been carrying out a review of the 2012 CT [Corporation Tax] period. During the course of this review, it was established that [Perrigo] claimed deductions under Case I [trading income] for amortisation of Intellectual property. A brief note was forwarded by you outlining the reasoning behind the treatment of this amortisation as an income expense. On the day of the meeting we would like this to be expanded upon. We would like you to detail the accounting standards that are used to treat IP when capitalized, amortised and when ultimately sold. You stated in your note that [Perrigo] is engaged in the “the [sic] purchase, development, and exploitation of the rights to pharmaceutical products, the sale of pharmaceutical products”, you listed several IP acquisitions throughout the years. We would like you to provide us with a detailed history of the company showing its acquisitions and disposals of IP throughout the years. We would also like you to show us how the business operates in seeking to acquire, develop, exploit and dispose of said IP. We would like you to expand upon the history of [Perrigo’s] ownership of the Tysabri IP; its initial development, the acquisition of the original licences, expenses including development incurred by [Perrigo] on the IP. We would like you to provide a copy of the original Tysabri collaboration agreement (and any amendments made throughout its life cycle) in place between [Perrigo] and Biogen before the disposal of [Perrigo’s] share. We would like you to provide us with an analysis of the various income streams of [Perrigo] which contribute to the top line Revenue figure in the Income statement in 2012 and 2013 (including product revenue from discontinued operations). In particular we are interested in the various income streams attributable to the exploitation of Tysabri in the years preceding the Biogen agreement and following its disposal. We would like to have an initial discussion where you provide an overview of the Tysabri agreement/sale that was made with Biogen in April, 2013. (emphasis added). II. March 1, 2018 Form 10-K Perrigo’s March 1, 2018 Form 10-K included the following disclosure: “We have ongoing audits in multiple other jurisdictions the resolution of which remains uncertain. . . . The Ireland Tax Authority is currently auditing our years ended December 31, 2012 and December 31, 2013.” This same statement was repeated in Perrigo’s May 8, 2018 Form 10-Q and its August 9, 2018 Form 10-Q.1

1 Perrigo’s March 23, 2018 definitive proxy statement filed on Schedule 14A with the SEC also referenced the March 2018 10-K. Plaintiffs allege that this constitutes another repetition of the statements in the March 2018 10-K. III. The Audit Findings Letter On October 30, 2018, Irish Revenue sent a letter describing the findings of its audit (the “Audit Findings Letter”) to Perrigo. The Letter began, “Please find below our findings

arising from the audit . . . . We invite you now to inform us of your view on the findings. If you disagree with the findings, please outline the basis for your position by 20 November 2018.” The Letter went on to note that the Tysabri transaction had been “treated as a Case I receipt” -- that is, as trading income subject to the 12.5% tax rate -- on Perrigo’s 2013 tax return. The Letter summarized Perrigo’s arguments in favor of treating the proceeds as trading income and Irish Revenue’s reasons for rejecting those arguments, concluding that Perrigo “should have applied a capital treatment to its IP and to the Tysabri IP in particular.” The Letter described this in various places as a “revised treatment” or “proposed treatment.”

The Letter provided detailed calculations of how the capital treatment would change Perrigo’s tax filings and found that Perrigo had a tax liability of approximately €1.6 billion, or $1.9 billion.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Novak v. Kasaks
216 F.3d 300 (Second Circuit, 2000)
Kleinman v. Elan Corp., plc
706 F.3d 145 (Second Circuit, 2013)
Bolt v. Merrimack Pharmaceuticals, Inc.
503 F.3d 913 (Ninth Circuit, 2007)
In re Vivendi, S.A. Secs. Litig.
838 F.3d 223 (Second Circuit, 2016)
In re Lions Gate Entertainment Corp. Securities Litigation
165 F. Supp. 3d 1 (S.D. New York, 2016)
Menaldi v. Och-Ziff Capital Management Group LLC
277 F. Supp. 3d 500 (S.D. New York, 2017)
Nielsen v. Rabin
746 F.3d 58 (Second Circuit, 2014)
Loginovskaya v. Batratchenko
764 F.3d 266 (Second Circuit, 2014)
Stratte-McClure v. Stanley
776 F.3d 94 (Second Circuit, 2015)
Sanderson v. Bagell, Josephs, Levine & Co.
781 F.3d 638 (Second Circuit, 2015)
Employees' Retirement System v. Blanford
794 F.3d 297 (Second Circuit, 2015)
Tongue v. Sanofi
816 F.3d 199 (Second Circuit, 2016)
Indiana Public Retirement System v. SAIC, Inc.
818 F.3d 85 (Second Circuit, 2016)
Singh v. Cigna Corp.
918 F.3d 57 (Second Circuit, 2019)

Cite This Page — Counsel Stack

Bluebook (online)
Masih v. Perrigo Company PLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/masih-v-perrigo-company-plc-nysd-2020.